SLDB (Solid Biosciences) Earnings per Share (Diluted) : $-3.01 (TTM As of Mar. 2025)

View and export this data going back to 2018. Start your Free Trial

What is Solid Biosciences Earnings per Share (Diluted)?

Solid Biosciences's Earnings per Share (Diluted) for the three months ended in Mar. 2025 was $-0.59. Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.01.

Solid Biosciences's EPS (Basic) for the three months ended in Mar. 2025 was $-0.59. Its EPS (Basic) for the trailing twelve months (TTM) ended in Mar. 2025 was $-3.01.

Solid Biosciences's EPS without NRI for the three months ended in Mar. 2025 was $-0.57. Its EPS without NRI for the trailing twelve months (TTM) ended in Mar. 2025 was $-2.87.

During the past 3 years, the average EPS without NRIGrowth Rate was 33.80% per year. During the past 5 years, the average EPS without NRI Growth Rate was 40.70% per year.

During the past 10 years, Solid Biosciences's highest 3-Year average EPS without NRI Growth Rate was 42.10% per year. The lowest was -89.60% per year. And the median was 33.10% per year.

Solid Biosciences Earnings per Share (Diluted) Historical Data

The historical data trend for Solid Biosciences's Earnings per Share (Diluted) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Solid Biosciences Earnings per Share (Diluted) Chart

Solid Biosciences Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Earnings per Share (Diluted)

Get a 7-Day Free Trial

-25.50

-10.14

-10.10

-4.83

-3.06

Solid Biosciences Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Earnings per Share (Diluted)	Get a 7-Day Free Trial															-0.64	-0.61	-0.79	-1.02	-0.59

Competitive Comparison of Solid Biosciences's Earnings per Share (Diluted)

For the Biotechnology subindustry, Solid Biosciences's PE Ratio, along with its competitors' market caps and PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Solid Biosciences's PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Solid Biosciences's PE Ratio distribution charts can be found below:

* The bar in red indicates where Solid Biosciences's PE Ratio falls into.

Save Embed

;

Save Embed

;

Solid Biosciences Earnings per Share (Diluted) Calculation

Earnings Per Share (EPS) is the amount of earnings per outstanding share of the company's stock. In calculating earnings per share, the dividends of preferred stocks need to subtracted from the total net income first.

Solid Biosciences's Earnings Per Share (Diluted) for the fiscal year that ended in Dec. 2024 is calculated as

Diluted Earnings Per Share (A: Dec. 2024 )	=	(Net Income	-	Preferred Dividends)	/	Shares Outstanding (Diluted Average)
	=	(-124.697	-	0)	/	40.817
	=	-3.06

Solid Biosciences's Earnings Per Share (Diluted) for the quarter that ended in Mar. 2025 is calculated as

Diluted Earnings Per Share (Q: Mar. 2025 )	=	(Net Income	-	Preferred Dividends	/	Shares Outstanding (Diluted Average)
	=	(-39.282	-	0)	/	66.341
	=	-0.59

Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $-3.01

Companies also reported diluted shares in their financial reports. Diluted shares include the shares of convertibles or warrants outstanding.

Solid Biosciences (NAS:SLDB) Earnings per Share (Diluted) Explanation

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Solid Biosciences Earnings per Share (Diluted) Related Terms

Thank you for viewing the detailed overview of Solid Biosciences's Earnings per Share (Diluted) provided by GuruFocus.com. Please click on the following links to see related term pages.

Solid Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Solid Biosciences Inc (NAS:SLDB) » Definitions » Earnings per Share (Diluted)

Comparable Companies

Traded in Other Exchanges

N/A

Address

500 Rutherford Avenue, Third Floor, Charlestown, MA, USA, 02129

Website

https://www.solidbio.com

Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.

Executives

Clare Kahn	director	141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Perceptive Life Sciences Master Fund Ltd	director, 10 percent owner	C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003
Bain Capital Life Sciences Investors, Llc	10 percent owner	200 CLARENDON STREET, BOSTON MA 02116
Gabriel Brooks	officer: Chief Medical Officer	C/O SOLID BIOSCIENCES INC., 500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
David T Howton	officer: See Remarks	VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
Paul Herzich	officer: Chief Technology Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Jessie Hanrahan	officer: Chief Regulatory Officer	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Kevin Tan	officer: CFO & Treasurer	20 HICKORY ROAD, WELLESLEY MA 02482
Ilan Ganot	director, officer: Chief Executive Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Alexander Cumbo	director, officer: President and CEO	215 FIRST STREET, SUITE 415, CAMBRIDGE MA 02142
Ra Capital Healthcare Fund Lp	director, 10 percent owner	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Jennifer Marlowe	officer: CSO, FA & Cardiac	500 RUTHERFORD AVENUE, THIRD FLOOR, CHARLESTOWN MA 02129
Carl Ashley Morris	officer: Chief Scientific Officer	C/O SOLID BIOSCIENCES, LLC, 141 PORTLAND STREET, FIFTH FLOOR, CAMBRIDGE MA 02139
Georgia Keresty	director	C/O ASPEN TECHNOLOGY, INC., 20 CROSBY DRIVE, BEDFORD MA 01730
Perceptive Venture Advisors, Llc	director, 10 percent owner	51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003